A citation-based method for searching scientific literature

Hyun Cheol Chung, Willeke Ros, Jean-Pierre Delord, Ruth Perets, Antoine Italiano, Ronnie Shapira-Frommer, Lyudmila Manzuk, Sarina A Piha-Paul, Lei Xu, Susan Zeigenfuss, Scott K Pruitt, Alexandra Leary. J Clin Oncol 2019
Times Cited: 375







List of co-cited articles
599 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer.
Nicoletta Colombo, Coraline Dubot, Domenica Lorusso, M Valeria Caceres, Kosei Hasegawa, Ronnie Shapira-Frommer, Krishnansu S Tewari, Pamela Salman, Edwin Hoyos Usta, Eduardo Yañez,[...]. N Engl J Med 2021
89
29

Safety and Efficacy of Pembrolizumab in Advanced, Programmed Death Ligand 1-Positive Cervical Cancer: Results From the Phase Ib KEYNOTE-028 Trial.
Jean-Sebastien Frenel, Christophe Le Tourneau, Bert O'Neil, Patrick A Ott, Sarina A Piha-Paul, Carlos Gomez-Roca, Emilie M J van Brummelen, Hope S Rugo, Shari Thomas, Sanatan Saraf,[...]. J Clin Oncol 2017
237
25

Safety and Efficacy of Nivolumab Monotherapy in Recurrent or Metastatic Cervical, Vaginal, or Vulvar Carcinoma: Results From the Phase I/II CheckMate 358 Trial.
R Wendel Naumann, Antoine Hollebecque, Tim Meyer, Michael-John Devlin, Ana Oaknin, Joseph Kerger, Jose M López-Picazo, Jean-Pascal Machiels, Jean-Pierre Delord, Thomas R J Evans,[...]. J Clin Oncol 2019
142
24

Improved survival with bevacizumab in advanced cervical cancer.
Krishnansu S Tewari, Michael W Sill, Harry J Long, Richard T Penson, Helen Huang, Lois M Ramondetta, Lisa M Landrum, Ana Oaknin, Thomas J Reid, Mario M Leitao,[...]. N Engl J Med 2014
784
21

Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.
Hyuna Sung, Jacques Ferlay, Rebecca L Siegel, Mathieu Laversanne, Isabelle Soerjomataram, Ahmedin Jemal, Freddie Bray. CA Cancer J Clin 2021
21

Cervical cancer.
Paul A Cohen, Anjua Jhingran, Ana Oaknin, Lynette Denny. Lancet 2019
680
15

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.
Freddie Bray, Jacques Ferlay, Isabelle Soerjomataram, Rebecca L Siegel, Lindsey A Torre, Ahmedin Jemal. CA Cancer J Clin 2018
14

Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study.
Aurelien Marabelle, Dung T Le, Paolo A Ascierto, Anna Maria Di Giacomo, Ana De Jesus-Acosta, Jean-Pierre Delord, Ravit Geva, Maya Gottfried, Nicolas Penel, Aaron R Hansen,[...]. J Clin Oncol 2020
856
14

Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study.
Aurélien Marabelle, Marwan Fakih, Juanita Lopez, Manisha Shah, Ronnie Shapira-Frommer, Kazuhiko Nakagawa, Hyun Cheol Chung, Hedy L Kindler, Jose A Lopez-Martin, Wilson H Miller,[...]. Lancet Oncol 2020
619
13

Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240).
Krishnansu S Tewari, Michael W Sill, Richard T Penson, Helen Huang, Lois M Ramondetta, Lisa M Landrum, Ana Oaknin, Thomas J Reid, Mario M Leitao, Helen E Michael,[...]. Lancet 2017
243
13

Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis.
Marc Arbyn, Elisabete Weiderpass, Laia Bruni, Silvia de Sanjosé, Mona Saraiya, Jacques Ferlay, Freddie Bray. Lancet Glob Health 2020
13

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency.
Dung T Le, Jennifer N Uram, Hao Wang, Bjarne R Bartlett, Holly Kemberling, Aleksandra D Eyring, Andrew D Skora, Brandon S Luber, Nilofer S Azad, Dan Laheru,[...]. N Engl J Med 2015
12

Enhanced expression of PD L1 in cervical intraepithelial neoplasia and cervical cancers.
Louisa Mezache, Bernard Paniccia, Angelique Nyinawabera, Gerard J Nuovo. Mod Pathol 2015
145
12

Prognostic effect of different PD-L1 expression patterns in squamous cell carcinoma and adenocarcinoma of the cervix.
A Marijne Heeren, Simone Punt, Maaike Cg Bleeker, Katja N Gaarenstroom, Jacobus van der Velden, Gemma G Kenter, Tanja D de Gruijl, Ekaterina S Jordanova. Mod Pathol 2016
154
12


Phase II evaluation of nivolumab in the treatment of persistent or recurrent cervical cancer (NCT02257528/NRG-GY002).
Alessandro D Santin, Wei Deng, Michael Frumovitz, Natalia Buza, Stefania Bellone, Warner Huh, Samir Khleif, Heather A Lankes, Elena S Ratner, Roisin E O'Cearbhaill,[...]. Gynecol Oncol 2020
43
27

Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study.
Robert L Coleman, Domenica Lorusso, Christine Gennigens, Antonio González-Martín, Leslie Randall, David Cibula, Bente Lund, Linn Woelber, Sandro Pignata, Frederic Forget,[...]. Lancet Oncol 2021
50
24

Expression of PD-L1 and presence of CD8-positive T cells in pre-treatment specimens of locally advanced cervical cancer.
Emeka K Enwere, Elizabeth N Kornaga, Michelle Dean, Theodora A Koulis, Tien Phan, Maria Kalantarian, Martin Köbel, Prafull Ghatage, Anthony M Magliocco, Susan P Lees-Miller,[...]. Mod Pathol 2017
87
12

Camrelizumab Plus Apatinib in Patients With Advanced Cervical Cancer (CLAP): A Multicenter, Open-Label, Single-Arm, Phase II Trial.
Chunyan Lan, Jingxian Shen, Yin Wang, Jundong Li, Zhimin Liu, Mian He, Xinping Cao, Jiayu Ling, Jiaming Huang, Min Zheng,[...]. J Clin Oncol 2020
54
20

Phase II study of the safety and efficacy of the anti-PD-1 antibody balstilimab in patients with recurrent and/or metastatic cervical cancer.
David M O'Malley, Ana Oaknin, Bradley J Monk, Frédéric Selle, Carlos Rojas, Laurence Gladieff, Dominique Berton, Alexandra Leary, Kathleen N Moore, Maria D P Estevez-Diz,[...]. Gynecol Oncol 2021
17
64

Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade.
Dung T Le, Jennifer N Durham, Kellie N Smith, Hao Wang, Bjarne R Bartlett, Laveet K Aulakh, Steve Lu, Holly Kemberling, Cara Wilt, Brandon S Luber,[...]. Science 2017
9

Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer.
Naiyer A Rizvi, Matthew D Hellmann, Alexandra Snyder, Pia Kvistborg, Vladimir Makarov, Jonathan J Havel, William Lee, Jianda Yuan, Phillip Wong, Teresa S Ho,[...]. Science 2015
9

Management of patients with recurrent/advanced cervical cancer beyond first line platinum regimens: Where do we stand? A literature review.
Stergios Boussios, Esmeralda Seraj, George Zarkavelis, Dimitrios Petrakis, Aristomenes Kollas, Aikaterini Kafantari, Abraam Assi, Konstantina Tatsi, Nicholas Pavlidis, George Pentheroudakis. Crit Rev Oncol Hematol 2016
99
9

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.
Suzanne L Topalian, F Stephen Hodi, Julie R Brahmer, Scott N Gettinger, David C Smith, David F McDermott, John D Powderly, Richard D Carvajal, Jeffrey A Sosman, Michael B Atkins,[...]. N Engl J Med 2012
8

Association of Polymerase e-Mutated and Microsatellite-Instable Endometrial Cancers With Neoantigen Load, Number of Tumor-Infiltrating Lymphocytes, and Expression of PD-1 and PD-L1.
Brooke E Howitt, Sachet A Shukla, Lynette M Sholl, Lauren L Ritterhouse, Jaclyn C Watkins, Scott Rodig, Elizabeth Stover, Kyle C Strickland, Alan D D'Andrea, Catherine J Wu,[...]. JAMA Oncol 2015
389
8

PD-1 blockade in recurrent or metastatic cervical cancer: Data from cemiplimab phase I expansion cohorts and characterization of PD-L1 expression in cervical cancer.
Danny Rischin, Marta Gil-Martin, Antonio González-Martin, Irene Braña, June Y Hou, Daniel Cho, Gerald S Falchook, Silvia Formenti, Salma Jabbour, Kathleen Moore,[...]. Gynecol Oncol 2020
22
36

Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck.
Robert L Ferris, George Blumenschein, Jerome Fayette, Joel Guigay, A Dimitrios Colevas, Lisa Licitra, Kevin Harrington, Stefan Kasper, Everett E Vokes, Caroline Even,[...]. N Engl J Med 2016
7

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.
James Larkin, Vanna Chiarion-Sileni, Rene Gonzalez, Jean Jacques Grob, C Lance Cowey, Christopher D Lao, Dirk Schadendorf, Reinhard Dummer, Michael Smylie, Piotr Rutkowski,[...]. N Engl J Med 2015
7

A Phase II Study of Tumor-infiltrating Lymphocyte Therapy for Human Papillomavirus-associated Epithelial Cancers.
Sanja Stevanović, Sarah R Helman, John R Wunderlich, Michelle M Langhan, Stacey L Doran, Mei Li M Kwong, Robert P T Somerville, Christopher A Klebanoff, Udai S Kammula, Richard M Sherry,[...]. Clin Cancer Res 2019
107
7

Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group study.
Bradley J Monk, Michael W Sill, D Scott McMeekin, David E Cohn, Lois M Ramondetta, Cecelia H Boardman, Jo Benda, David Cella. J Clin Oncol 2009
418
7


Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
C Marth, F Landoni, S Mahner, M McCormack, A Gonzalez-Martin, N Colombo. Ann Oncol 2017
299
7

Sequential Ipilimumab After Chemoradiotherapy in Curative-Intent Treatment of Patients With Node-Positive Cervical Cancer.
Jyoti S Mayadev, Danielle Enserro, Yvonne G Lin, Diane M Da Silva, Heather A Lankes, Carol Aghajanian, Sharad Ghamande, Kathleen N Moore, Vanessa A Kennedy, Paula M Fracasso,[...]. JAMA Oncol 2020
38
18

Phase II study of atezolizumab in combination with bevacizumab in patients with advanced cervical cancer.
Claire F Friedman, Alexandra Snyder Charen, Qin Zhou, Michael A Carducci, Alexandre Buckley De Meritens, Bradley R Corr, Siqing Fu, Travis J Hollmann, Alexia Iasonos, Jason A Konner,[...]. J Immunother Cancer 2020
24
29

Survival with Cemiplimab in Recurrent Cervical Cancer.
Krishnansu S Tewari, Bradley J Monk, Ignace Vergote, Austin Miller, Andreia C de Melo, Hee-Seung Kim, Yong Man Kim, Alla Lisyanskaya, Vanessa Samouëlian, Domenica Lorusso,[...]. N Engl J Med 2022
19
36

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial.
Tony S K Mok, Yi-Long Wu, Iveta Kudaba, Dariusz M Kowalski, Byoung Chul Cho, Hande Z Turna, Gilberto Castro, Vichien Srimuninnimit, Konstantin K Laktionov, Igor Bondarenko,[...]. Lancet 2019
6

Improved survival with ipilimumab in patients with metastatic melanoma.
F Stephen Hodi, Steven J O'Day, David F McDermott, Robert W Weber, Jeffrey A Sosman, John B Haanen, Rene Gonzalez, Caroline Robert, Dirk Schadendorf, Jessica C Hassel,[...]. N Engl J Med 2010
6

Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma.
Joaquim Bellmunt, Ronald de Wit, David J Vaughn, Yves Fradet, Jae-Lyun Lee, Lawrence Fong, Nicholas J Vogelzang, Miguel A Climent, Daniel P Petrylak, Toni K Choueiri,[...]. N Engl J Med 2017
6



Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade.
Yoshiko Iwai, Masayoshi Ishida, Yoshimasa Tanaka, Taku Okazaki, Tasuku Honjo, Nagahiro Minato. Proc Natl Acad Sci U S A 2002
6

Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden.
Zachary R Chalmers, Caitlin F Connelly, David Fabrizio, Laurie Gay, Siraj M Ali, Riley Ennis, Alexa Schrock, Brittany Campbell, Adam Shlien, Juliann Chmielecki,[...]. Genome Med 2017
6

Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Barbara Burtness, Kevin J Harrington, Richard Greil, Denis Soulières, Makoto Tahara, Gilberto de Castro, Amanda Psyrri, Neus Basté, Prakash Neupane, Åse Bratland,[...]. Lancet 2019
914
6

T-Cell-Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated With Pembrolizumab Across 20 Cancers: KEYNOTE-028.
Patrick A Ott, Yung-Jue Bang, Sarina A Piha-Paul, Albiruni R Abdul Razak, Jaafar Bennouna, Jean-Charles Soria, Hope S Rugo, Roger B Cohen, Bert H O'Neil, Janice M Mehnert,[...]. J Clin Oncol 2019
373
6

Tumor Mutational Burden and Response Rate to PD-1 Inhibition.
Mark Yarchoan, Alexander Hopkins, Elizabeth M Jaffee. N Engl J Med 2017
6

Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix.
W A Peters, P Y Liu, R J Barrett, R J Stock, B J Monk, J S Berek, L Souhami, P Grigsby, W Gordon, D S Alberts. J Clin Oncol 2000
6

Integrated genomic characterization of endometrial carcinoma.
Cyriac Kandoth, Nikolaus Schultz, Andrew D Cherniack, Rehan Akbani, Yuexin Liu, Hui Shen, A Gordon Robertson, Itai Pashtan, Ronglai Shen, Christopher C Benz,[...]. Nature 2013
6

Safety and Antitumor Activity of Pembrolizumab in Advanced Programmed Death Ligand 1-Positive Endometrial Cancer: Results From the KEYNOTE-028 Study.
Patrick A Ott, Yung-Jue Bang, Dominique Berton-Rigaud, Elena Elez, Michael J Pishvaian, Hope S Rugo, Igor Puzanov, Janice M Mehnert, Kyaw L Aung, Juanita Lopez,[...]. J Clin Oncol 2017
249
6

Revised FIGO staging for carcinoma of the cervix uteri.
Neerja Bhatla, Jonathan S Berek, Mauricio Cuello Fredes, Lynette A Denny, Seija Grenman, Kanishka Karunaratne, Sean T Kehoe, Ikuo Konishi, Alexander B Olawaiye, Jaime Prat,[...]. Int J Gynaecol Obstet 2019
324
6

Association of Ipilimumab With Safety and Antitumor Activity in Women With Metastatic or Recurrent Human Papillomavirus-Related Cervical Carcinoma.
Stephanie Lheureux, Marcus O Butler, Blaise Clarke, Mihaela C Cristea, Lainie P Martin, Katia Tonkin, Gini F Fleming, Anna V Tinker, Hal W Hirte, Daliah Tsoref,[...]. JAMA Oncol 2018
70
8


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.